
Emerging SME Services · NSE
Zenith Drugs Limited, founded in 2000, is a pharmaceutical company that manufactures and trades affordable, high-quality medicines, including various generic products. The company operates under WHO-GMP guidelines and holds an ISO 9001:2015 certification, reflecting its focus on quality. It offers a wide product range such as ORS powder, liquid orals, ointments, liquid externals, and capsules, with over 600 products approved by the Food & Drugs Administration and 325 currently in production. Zenith Drugs is expanding by setting up a new manufacturing facility in Muradpura, Depalpur, Indore, and it also exports its products to multiple regions including Central America, Africa, Southeast Asia, and South Asia. The company provides third-party manufacturing services to well-known pharmaceutical brands like Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, and as of March 31, 2023, it employs 89 people, including both payroll and contract staff.
Price Band
₹75 – ₹79
Issue Size
₹40.68 Cr
Lot Size
1600 shares
GMP
+44.3%
Est. Listing
₹114
at current GMP
Subscribed
179.07x
overall
Open
19 Feb 2024
Close
22 Feb 2024
Allotment
23 Feb 2024
Refund
24 Feb 2024
Demat Credit
25 Feb 2024
Listing
27 Feb 2024
Overall Subscription
179.07x
Total Demand
QIB Multiplier
106.72x
Institutions & Funds
NII / HNI
369.94x
High Net-Worth
Retail (RII)
138.57x
Individual Bidders
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 859,200 | 91,697,600 | 106.72x |
| NIB | 644,800 | 238,539,200 | 369.94x |
| RETAIL | 1,504,000 | 208,404,800 | 138.57x |
| Total | 3,008,000 | 538,641,600 | 179.07x |
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| Retail (RII) | 1,126 | 156,030 | 138.57x |
| HNIs (10L +) | 7 | 2,590 | 369.94x |
| HNIs (2-10L) | 34 | 12,578 | 369.94x |
| Total Applications | 1,167 | 171,198 | 146.70x |
Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.
Zenith Drugs Limited is bringing an initial public offering (IPO) in the Emerging SME Services sector with an aggregate issue size of ₹40.68 Crores. The shares are offered at a price band of ₹75 to ₹79 per equity share on NSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 1600 shares (approx. ₹1,26,400 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2024-02-25, while un-allotted funds or UPI block mandates will be released on 2024-02-24.
The latest Grey Market Premium (GMP) for Zenith Drugs Limited IPO is ₹35 per equity share. Based on the upper price band of ₹75 to ₹79 per equity share, the estimated listing price is ₹114 (+44.3% expected listing gain).
With a lot size of 1600 shares and current GMP of ₹35, the expected profit per application lot is approx ₹56,000 (+44.3% gain). Minimum application cost is approx ₹1,26,400.
The Zenith Drugs Limited IPO aggregate issue size is ₹40.68 Crores with an equity price band set at ₹75 to ₹79 per equity share. The retail lot size is 1600 shares requiring a minimum capital outlay of approx. ₹1,26,400.
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 179.07x (Retail: 138.57x, QIB: 106.72x, NII: 369.94x). You can track live multiples directly on our dedicated subscription page.
The basis of allotment will be published on the official registrar portal (Bigshare Services Private Limited) and the BSE status verification website on or around 2024-02-23. Investors can verify status using PAN card or application number.
Zenith Drugs Limited shares are scheduled to list on NSE on 2024-02-27.